Alnylam Pharma (ALNY) Tops Q3 EPS by 21c

Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.06), $0.21 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $17.1 million versus the consensus estimate of $24.65 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15